2015
An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate
Gueorguieva R, Wu R, Tsai WM, O’Connor P, Fucito L, Zhang H, O’Malley S. An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate. European Neuropsychopharmacology 2015, 25: 1586-1599. PMID: 26141511, PMCID: PMC4600651, DOI: 10.1016/j.euroneuro.2015.06.006.Peer-Reviewed Original ResearchConceptsAcamprosate effectHeavy drinkingShort abstinenceEnhanced treatment responseMonths of treatmentSubgroup of patientsBody mass indexDrug plasma levelsIdentification of subgroupsBetter prognosisLower BMIMass indexPlasma levelsGlutamatergic hyperactivityTreatment responseAcamprosateCOMBINE StudyPrior treatmentLarger studyConsecutive daysAbstinencePretreatment abstinenceTreatment effectsCognitive inefficiencySubgroups
2013
Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response
Gueorguieva R, Wu R, Krystal JH, Donovan D, O'Malley SS. Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response. Addictive Behaviors 2013, 38: 2119-2127. PMID: 23435273, PMCID: PMC3595348, DOI: 10.1016/j.addbeh.2013.01.024.Peer-Reviewed Original ResearchConceptsPercent heavy drinking daysAdherence trajectoriesExcellent adherersPercent days abstinentPatient characteristicsMedication adherenceTreatment outcomesMedication adherence trajectoriesPatterns of treatmentHeavy drinking daysPatterns of adherenceExcellent medication adherenceLack of benefitTrajectories of adherenceIntervention main effectsActive medicationAdverse eventsPharmacologic treatmentHigher percent days abstinentTreatment adherenceTreatment modalitiesWorse outcomesTreatment responseDays abstinentDrinking days
2011
Trajectories of Depression Severity in Clinical Trials of Duloxetine: Insights Into Antidepressant and Placebo Responses
Gueorguieva R, Mallinckrodt C, Krystal JH. Trajectories of Depression Severity in Clinical Trials of Duloxetine: Insights Into Antidepressant and Placebo Responses. JAMA Psychiatry 2011, 68: 1227-1237. PMID: 22147842, PMCID: PMC3339151, DOI: 10.1001/archgenpsychiatry.2011.132.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntidepressive AgentsData Interpretation, StatisticalDepressive Disorder, MajorDouble-Blind MethodDuloxetine HydrochlorideFemaleHumansLinear ModelsMalePatient DropoutsPlacebo EffectPsychiatric Status Rating ScalesRandomized Controlled Trials as TopicSelective Serotonin Reuptake InhibitorsSeverity of Illness IndexThiophenesTreatment OutcomeConceptsSelective serotonin reuptake inhibitorsPlacebo-treated patientsComparator selective serotonin reuptake inhibitorsHAM-D scoresClinical trialsAntidepressant treatmentPlacebo responseMajor depressionDouble-blind clinical trialHigh placebo response rateSerotonergic antidepressant treatmentPlacebo response ratesSerotonin reuptake inhibitorsAntidepressant nonrespondersPlacebo armMost patientsAntidepressant respondersMedication risksReuptake inhibitorsSerotonergic antidepressantsResponder statusTreatment responseClinical trajectoriesDepression scoresDepression severity